Title |
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
|
---|---|
Published in |
BMC Cancer, November 2011
|
DOI | 10.1186/1471-2407-11-505 |
Pubmed ID | |
Authors |
Charlotte M Huijts, Saskia J Santegoets, Alfons J van den Eertwegh, Laura S Pijpers, John B Haanen, Tanja D de Gruijl, Henk M Verheul, Hans J van der Vliet |
Abstract |
For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to prolong progression free survival. Intriguingly, inhibition of mTOR also promotes expansion of immunosuppressive regulatory T cells (Tregs) that can inhibit anti-tumor immune responses in a clinically relevant way in various tumor types including RCC. This study intends to investigate whether the antitumor efficacy of everolimus can be increased by preventing the detrimental everolimus induced expansion of Tregs using a metronomic schedule of cyclophosphamide. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 2% |
Unknown | 62 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 22% |
Student > Ph. D. Student | 10 | 16% |
Student > Bachelor | 6 | 10% |
Student > Doctoral Student | 6 | 10% |
Student > Master | 6 | 10% |
Other | 7 | 11% |
Unknown | 14 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 40% |
Agricultural and Biological Sciences | 7 | 11% |
Immunology and Microbiology | 5 | 8% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Nursing and Health Professions | 3 | 5% |
Other | 5 | 8% |
Unknown | 15 | 24% |